Allyson Mateja1, Qinlu Wang2, Jack Chovanec3, Jiwon Kim3, Kenneth J Wilson4, Lawrence B Schwartz5, Sarah C Glover6, Melody C Carter3, Dean D Metcalfe3, Erica Brittain7, Jonathan J Lyons8. 1. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research. 2. Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md. 3. Laboratory of Allergic Diseases, NIH, Bethesda, Md. 4. Division of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, Miss. 5. Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, Virginia Commonwealth University, Richmond, Va. 6. Division of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, Miss; Division of Gastroenterology, Department of Medicine, University of Florida, Gainesville, Fla. 7. Biostatistics Research Branch, NIAID, NIH, Bethesda, Md. 8. Laboratory of Allergic Diseases, NIH, Bethesda, Md. Electronic address: jonathan.lyons@nih.gov.
Abstract
BACKGROUND: Acute increases of ≥20% + 2 ng/mL (20 + 2 rule) over basal serum tryptase (BST) is the recommended threshold supporting a clinical diagnosis of anaphylaxis. Prospective studies have demonstrated high sensitivity for this algorithm after parenteral exposure, but specificity has not been evaluated. OBJECTIVE: We sought to define a serum tryptase change that distinguishes baseline variability from anaphylaxis on the basis of intraindividual variation in BST. METHODS: Ninety-three total subjects with atopy (n = 62) or hereditary α-tryptasemia (HαT) (n = 31) and ≥2 BST measurements were identified. Sequential BST variability measurements were modeled and threshold ratios that optimized sensitivity and/or specificity determined. Models were tested in 22 individuals with physician-diagnosed anaphylaxis and validated in independent cohorts of individuals with HαT (n = 33), indolent systemic mastocytosis (ISM) (n = 52), and ISM + HαT (n = 12). Mature tryptase levels were measured in HαT (n = 19) and ISM (n = 20). An online application was developed for clinical use. RESULTS: As a result of BST variability, 9.7% (9/93) of primary cohort patients, and 18% (6/33) of HαT, 30% (16/53) of ISM, and 25% (3/12) of ISM + HαT patients from validation cohorts met the 20 + 2 rule despite absent immediate hypersensitivity symptoms; mature tryptase was noncontributory among individuals with HαT or ISM at baseline. A ratio of acute tryptase/BST exceeding 1.685 provided the optimized diagnostic rule for jointly maximizing sensitivity and specificity. Statistically significant improvement in specificity relative to the 20 + 2 rule was observed among individuals with elevated BST caused by HαT and ISM. CONCLUSIONS: Using an acute tryptase/BST ratio of 1.685 improves specificity of measured changes among individuals with HαT and ISM while maintaining high sensitivity for confirmation of anaphylaxis. Published by Elsevier Inc.
BACKGROUND: Acute increases of ≥20% + 2 ng/mL (20 + 2 rule) over basal serum tryptase (BST) is the recommended threshold supporting a clinical diagnosis of anaphylaxis. Prospective studies have demonstrated high sensitivity for this algorithm after parenteral exposure, but specificity has not been evaluated. OBJECTIVE: We sought to define a serum tryptase change that distinguishes baseline variability from anaphylaxis on the basis of intraindividual variation in BST. METHODS: Ninety-three total subjects with atopy (n = 62) or hereditary α-tryptasemia (HαT) (n = 31) and ≥2 BST measurements were identified. Sequential BST variability measurements were modeled and threshold ratios that optimized sensitivity and/or specificity determined. Models were tested in 22 individuals with physician-diagnosed anaphylaxis and validated in independent cohorts of individuals with HαT (n = 33), indolent systemic mastocytosis (ISM) (n = 52), and ISM + HαT (n = 12). Mature tryptase levels were measured in HαT (n = 19) and ISM (n = 20). An online application was developed for clinical use. RESULTS: As a result of BST variability, 9.7% (9/93) of primary cohort patients, and 18% (6/33) of HαT, 30% (16/53) of ISM, and 25% (3/12) of ISM + HαT patients from validation cohorts met the 20 + 2 rule despite absent immediate hypersensitivity symptoms; mature tryptase was noncontributory among individuals with HαT or ISM at baseline. A ratio of acute tryptase/BST exceeding 1.685 provided the optimized diagnostic rule for jointly maximizing sensitivity and specificity. Statistically significant improvement in specificity relative to the 20 + 2 rule was observed among individuals with elevated BST caused by HαT and ISM. CONCLUSIONS: Using an acute tryptase/BST ratio of 1.685 improves specificity of measured changes among individuals with HαT and ISM while maintaining high sensitivity for confirmation of anaphylaxis. Published by Elsevier Inc.
Authors: Joana Vitte; Laurent Amadei; Marion Gouitaa; Soraya Mezouar; Laurent Zieleskiewicz; Jacques Albanese; Nicolas Bruder; David Lagier; Paul M Mertès; Jean-Louis Mège; Lawrence B Schwartz; Marc Leone Journal: Allergy Date: 2019-03-21 Impact factor: 13.146
Authors: R L Baretto; S Beck; J Heslegrave; C Melchior; O Mohamed; A Ekbote; A P Huissoon; M T Krishna Journal: Allergy Date: 2017-07-12 Impact factor: 13.146
Authors: Melody C Carter; Avanti Desai; Hirsh D Komarow; Yun Bai; Sarah T Clayton; Alicia S Clark; Karina N Ruiz-Esteves; Lauren M Long; Daly Cantave; Todd M Wilson; Linda M Scott; Olga Simakova; Mi-Yeon Jung; Jamie Hahn; Irina Maric; Dean D Metcalfe Journal: J Allergy Clin Immunol Date: 2017-06-16 Impact factor: 10.793
Authors: Sarah C Glover; Melody C Carter; Peter Korošec; Patrizia Bonadonna; Lawrence B Schwartz; Joshua D Milner; George H Caughey; Dean D Metcalfe; Jonathan J Lyons Journal: Ann Allergy Asthma Immunol Date: 2021-08-13 Impact factor: 6.248
Authors: Aubri M Waters; Hyun J Park; Andrew L Weskamp; Allyson Mateja; Megan E Kachur; Jonathan J Lyons; Benjamin J Rosen; Nathan A Boggs Journal: J Allergy Clin Immunol Pract Date: 2022-01-12